

1. Spatial separation of *Streptomyces* aerial mycelium during fermentation enhances secondary metabolite production.  
Balaji Muralikrishnan, Retnakumar R, Ranjit Ramachandran, Vinodh J S, Nijisha M, Arun K B, Laiza Paul, Syed Gulam Dastager, Vipin Mohan Dan, Ajay Kumar Ramakrishnan.doi: <https://doi.org/10.1101/2020.05.27.118091>
2. Putative TetR family transcriptional regulator Rv1019 of *Mycobacterium tuberculosis* is an auto-repressor and a negative regulator of *mfd-mazG* operon. Akhil Raj Pushparajan, Ranjit Ramachandran, Jijimole Gopi Reji, Ramakrishnan Ajay Kumar. bioRxiv 2020.02.10.941963; doi: <https://doi.org/10.1101/2020.02.10.941963>
3. Acetylation of isoniazid - a novel mechanism of isoniazid resistance in *Mycobacterium tuberculosis*. K. B. Arun, Aravind Madhavan, Billu Abraham, M. Balaji, K. C. Sivakumar, P. Nisha, R. Ajay Kumar. (2020). bioRxiv 2020.02.10.941252; doi: <https://doi.org/10.1101/2020.02.10.941252>
4. Comparative label-free lipidomic analysis of *Mycobacterium tuberculosis* during dormancy and reactivation. Sajith Raghunandan, Leny Jose, Vipin Gopinath and Ramakrishnan Ajay Kumar (2019). Sci. Rep. 2019 Mar 6;9(1):3660. DOI:10.1038/s41598-019-40051-5.
5. Dormant *Mycobacterium tuberculosis* converts isoniazid to the active drug in a Wayne's model of dormancy. Sajith Raghunandan, Leny Jose and Ramakrishnan Ajay Kumar (2018). *The Journal of Antibiotics*. 05 September 2018. Doi: 10.1038/s41429-018-0098-z.
6. Rv0474 is a copper-responsive transcriptional regulator that negatively regulates expression of RNA polymerase β subunit in *Mycobacterium tuberculosis*. Raghunandan S, Ramachandran R, Gomez RL, Sivasankar D, Bommakanti A, Kondapi AK, Varadarajan R and Kumar RA (2018). FEBS J. Aug. 18. doi: 10.11111.
7. *Streptomyces* sp metabolite(s) promotes Bax mediated intrinsic apoptosis and autophagy involving inhibition of mTOR pathway in cervical cancer cell lines. Dan VM, Muralikrishnan B, Sanawar R, J S V, Burkul BB, Srinivas KP, Lekshmi A, Pradeep NS, Dastager SG, Santhakumari B, Santhoshkumar TR, Kumar RA, Pillai MR. Sci Rep. 2018 Feb 12;8(1):2810.
8. Isolation and Characterization of Anti-mycobacterial Compounds from Fruits of *Aegle marmelos* (L.) Correa. Suja K P, Leny Jose, Divya Lakshmanan, Anu G Vidya, Reshma Nair RJ, and R Ajay Kumar (2017). *J Commun Dis.* 49(4): 32-38.
9. Anti-microbial activity of chrysomycin A produced by *Streptomyces* sp. against *Mycobacterium tuberculosis*.Balaji Muralikrishnan, Vipin Mohan Dan, J.S. Vinodh, Vellekkat Jamsheena, Ranjit Ramachandran, Sabu Thomas, Syed G. Dastager, K.

Santhosh Kumar, Ravi Shankar Lankalapalli and R Ajay Kumar (2017). RSC Adv., 7, 36335-36339.

10. The multiple stressresponsive transcriptional regulator Rv3334 of *Mycobacterium tuberculosis* is anautorepressor and a positive regulator of kstR. Gomez RL, Jose L, Ramachandran R, Raghunandanan S, Muralikrishnan B, Johnson JB, Krishnankutty SC, Mundayoor S and Kumar RA (2016). FEBS J. 283(16):3056-71.
11. Subunit Protein Vaccine Delivery System for Tuberculosis Based on Hepatitis B Virus Core VLP (HBc-VLP) Particles. Dhanasooraj D, Kumar RA and Mundayoor S (2016). Methods Mol Biol. 2016; 1404:377-92.
12. Hypothetical protein Rv3423.1 of *Mycobacterium tuberculosis* is a histone acetyltransferase. Jose L, Ramachandran R, Bhagavat R, Gomez RL, Chandran A, Raghunandanan S, Omkumar RV, Chandra N, Mundayoor S and Kumar RA (2016). FEBS J. 283(2):265-81.
13. *Mycobacterium tuberculosis* Infection Induces HDAC1-Mediated Suppression of *IL-12B* Gene Expression in Macrophages. Chandran A, Antony C, Jose L, Mundayoor S, Natarajan K and Kumar RA (2015). Front. Cell. Infect. Microbiol., Dec 2;5:90. <http://dx.doi.org/10.3389/fcimb.2015.00090>.
14. Profiling the Proteome of *Mycobacterium tuberculosis* during Dormancy and Reactivation. Gopinath V, Raghunandanan S, Gomez RL, Jose L, Surendran A, Ramachandran R, Pushparajan AR, Mundayoor S and Jaleel A, Kumar RA (2015). Mol Cell Proteomics. 14(8):2160-2176.
15. Resveratrol – a potential inhibitor of biofilm formation in *Vibrio cholerae*. Phytomedicine. Augustine N, Goel AK, Sivakumar KC, Kumar RA and Thomas S (2014). 2014 Feb 15;21(3):286-9.
16. Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles. Dhanasooraj D, Kumar RA and Mundayoor S. Int J Nanomedicine. 2013;8:835-43.
17. Efficient discrimination by MIRU-VNTRs of *Mycobacterium tuberculosis* clinical isolates belonging to the predominant SIT11/EAI3-IND ancestral genotypic lineage in Kerala, India. Joseph BV, Soman S, Hill V, Kumar RA, Rastogi N and Mundayoor S (2013). Int J Mycobacteriol. 2(4):244-7.
18. Molecular epidemiology of *Mycobacterium tuberculosis* isolates from Kerala, India using IS6110-RFLP, spoligotyping and MIRU-VNTRs. Joseph BV, Soman S, Radhakrishnan I, Hill V, Dhanasooraj D, Kumar RA, Rastogi N and Mundayoor S (2013). Infect Genet Evol. 16:157-64.
19. Whole-genome sequences of two clinical isolates of *Mycobacterium tuberculosis* from Kerala, South India. Madhavilatha GK, Joseph BV, Paul LK, Kumar RA, Hariharan R and Mundayoor S (2012). J Bacteriol. 194(16):4430. doi: 10.1128/JB.00453-12.

20. Comparative analysis of mycobacterial truncated hemoglobin promoters and the groEL2 promoter in free-living and intracellular mycobacteria. Joseph SV, Madhavilatha GK, Kumar RA and Mundayoor S (2012). Appl Environ Microbiol. 78(18):6499-506.
21. Standardization and evaluation of a tetraplex polymerase chain reaction to detect and differentiate *Mycobacterium tuberculosis* complex and nontuberculous Mycobacteria - a retrospective study on pulmonary TB patients. Anilkumar AK, Madhavilatha GK, Paul LK, Radhakrishnan I, Kumar RA, Mundayoor S (2012). Diagn Microbiol Infect Dis. 2012 Mar;72(3):239-47
22. Synthesis, antimicrobial, antimycobacterial and structure-activity relationship of substituted pyrazolo-, isoxazolo-, pyrimido- and mercaptopyrimidocyclohepta[b]indoles. Yamuna E, Kumar RA, Zeller M and Rajendra Prasad KJ (2012). Eur J Med Chem. 47(1):228-38.
23. Ethyl p-methoxycinnamate isolated from a traditional antituberculosis medicinal herb inhibits drug resistant strains of *Mycobacterium tuberculosis* in vitro. Lakshmanan D, Werngren J, Jose L, Suja KP, Nair MS ,Varma RL, Mundayoor S, Hoffner S and Kumar RA (2011). Fitoterapia 82: 757-761.
24. Drug resistance in *Mycobacterium tuberculosis* isolates from tuberculosis patients in Kerala, India. Joseph BV, Soman S, Radhakrishnan I, Madhavilatha GK, Paul LK, Mundayoor S and Kumar RA (2009). Int J Tuberc Lung Dis. 13(4):494-9.
25. Synthesis of novel highly functionalized biologically active polycyclic caged amides. James B, Viji S, Mathew S, Nair MS, Lakshmanan D and Kumar RA (2007). Tetrahedron Letters 48(35):6204-6208.
26. Interaction of papillomavirus E2 protein with the Brm chromatin remodeling complex leads to enhanced transcriptional activation. Kumar RA, Naidu SR, Wang X, Imbalzano AN and Androphy EJ (2007) J Virol 81(5):2213-20.
27. Presence of region of difference 1 among clinical isolates of *Mycobacterium tuberculosis* from India. Soman S, Joseph BV, Sarojini S, Kumar RA, Katoch VM and Mundayoor S. J Clin Microbiol. 2007 Oct;45(10):3480-1.
28. Implications of low frequency of IS6110 in fingerprinting field isolates of *Mycobacterium tuberculosis* from Kerala, India. Radhakrishnan I, K MY, Kumar RA and Mundayoor S (2001). J Clin Microbiol. 39(4):1683.
29. A single-step, eco-friendly method to extract DNA from *Mycobacterium tuberculosis* for polymerase chain reaction. Kumar RA, Indulakshmi R and Mundayoor S (2000). Anal Biochem. 15;286(2):310-2.
30. Functional characterization of the precursor and spliced forms of RecA protein of *Mycobacterium tuberculosis*. Kumar RA, Vaze MB, Chandra NR, Vijayan M and Muniyappa K (1996). Biochemistry 35(6):1793-802.